SCHEDULE: Athanor Capital, UGS Capital Disclose 15.7% Stake in Zura Bio

Athanor Capital and UGS Capital LLC jointly reported a 15.7% beneficial ownership stake in Zura Bio Limited's Class A Ordinary Shares.

Summary

• Athanor Capital and UGS Capital LLC (Reporting Persons) jointly filed a Schedule 13G, disclosing their beneficial ownership in Zura Bio Limited.
• The Reporting Persons collectively beneficially own 11,581,402 Class A Ordinary Shares of Zura Bio Limited.
• This ownership represents 15.7% of the outstanding Class A Ordinary Shares, based on 73,680,710 shares advised by the Issuer as outstanding.
• UGS Capital LLC owns all the shares of Athanor Capital, establishing a control relationship between the two reporting entities.
• Parvinder Thiara, a director of Athanor Capital and a Manager of UGS Capital LLC, previously served as a member of Zura Bio Limited's board of directors from June 22, 2023, until May 21, 2025.
• The Reporting Persons certified that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of Zura Bio Limited.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The filing is a routine disclosure of significant passive ownership, which can be seen as a vote of confidence from institutional investors. No negative information is presented, and the passive nature of the investment is explicitly stated.

Positives

• Significant institutional ownership (15.7%) by Athanor Capital and UGS Capital LLC indicates a substantial investment in Zura Bio Limited, potentially signaling confidence in the company's long-term prospects.
• The explicit certification that the shares were not acquired for the purpose of changing or influencing control suggests a passive investment stance, which can provide stability and reduce concerns about potential activist interventions.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain any forward-looking statements or guidance from Zura Bio Limited.

Management Comments

• The securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11.

Industry Context

This filing represents a routine regulatory disclosure of significant passive ownership by institutional investors in a publicly traded company. While the filing itself does not provide specific industry trends, the substantial stake in Zura Bio Limited, a company with 'Bio' in its name, suggests institutional interest in the biotechnology or pharmaceutical sector.

Comparison to Industry Standards

• A 15.7% beneficial ownership stake is a substantial position for institutional investors in a public company, aligning with typical large passive investment strategies seen across various industries.

Management Changes

Corporate Governance

Related Party Transactions

• Parvinder Thiara, a director of Athanor Capital and manager of UGS Capital LLC, previously served on Zura Bio Limited's board of directors from June 22, 2023, until May 21, 2025, indicating a past direct relationship between the reporting persons' management and the issuer.

Stakeholder Impact

• Shareholders: Increased transparency regarding significant institutional ownership. The passive nature of the investment (not seeking control) may reassure existing shareholders about the stability of the company's governance.
• Management: Awareness of a substantial institutional shareholder base, which may influence communication strategies and investor relations.

Next Steps

• Athanor Capital and UGS Capital LLC will file all subsequent amendments to this Schedule 13G jointly in accordance with Rule 13d-1(k) of the Securities Exchange Act of 1934, as amended.

Key Dates

Recommendation

This Schedule 13G filing is a routine disclosure of beneficial ownership and does not contain information that would fundamentally alter the investment thesis for Zura Bio Limited. The significant institutional stake by Athanor Capital and UGS Capital LLC is noted, but the certification of passive intent suggests no immediate catalyst for control changes or strategic shifts. Investors should 'hold' and continue to monitor Zura Bio's operational and financial performance as disclosed in other filings.

Keywords

Zura Bio Limited, Athanor Capital, UGS Capital LLC, Schedule 13G, Beneficial Ownership, Class A Ordinary Shares, Institutional Ownership, SEC Filing, G9TY5A101